-
Myeloma Solutions Fund targets multiple myeloma
A high-risk form of multiple myeloma (MM) known as t(4;14) is the focus of $2.2 million in research grants from the Myeloma Solutions Fund to two Dana-Farber Cancer Institute investigators.
-
Susan G. Komen invests in breakthrough breast cancer research
Since its inception in 1982, Susan G. Komen has invested nearly $1.1 billion to accelerate progress and drive innovation in breast cancer research.
-
Linda Gelb accelerates groundbreaking team science by supporting the Bridge Project
Art Gelb, a longtime Dana-Farber Cancer Institute Trustee and supporter, was deeply admired for his vision, intelligence, persistence, and philanthropic leadership.
-
Family carries forward legacy of the late Larry Lucchino
Larry Lucchino was known for many things in the world of baseball: serving as a top sports executive for more than four decades, being the man who “broke the curse” and led the Boston Red Sox to three World Series titles in nine years.
-
A year of milestones for the Dana-Farber Marathon Challenge team
On Monday, April 20, more than 500 runners completed the 130th Boston Marathon® as part of the 2026 Dana-Farber Marathon Challenge (DFMC) team.
-
Dana Building marks half a century
For four decades, the Dana Building at 44 Binney Street was a place of hope where cancer patients came for treatment and researchers worked to expand what was possible in cancer care. Now home to research laboratories and administrative offices, the building marks its 50th anniversary this year.
-
Dana-Farber Society Dinner
On Tuesday, May 19th, 250 members of the Dana-Farber Society (DFS)—visionary donors who have made a planned gift to Dana-Farber, the Jimmy Fund, Friends of Dana-Farber, or the Pan-Mass Challenge—gathered at the Fairmont Copley Plaza for the biennial DFS Dinner.
-
Dana-Farber researchers awarded CLL Society grants to expand treatment options for CLL
Chronic lymphocytic leukemia (CLL) research at Dana-Farber Cancer Institute is advancing through two grants from the CLL Society totaling $600,000.
-
The Ellison Foundation fuels innovation as an enduring partner
With renewed funding from The Ellison Foundation, Bill Lotter, PhD, Eliezer Van Allen, MD, and Robbie Majzner, MD, are conducting pioneering work with the potential to advance research and treatment across multiple cancer types.
-
Tina’s Wish opens new doors in ovarian cancer research
Ovarian cancer remains one of the most devastating cancers due to diagnosis often coming at a later stage.










